Alliance Global Partners Begins Coverage on Sensus Healthcare (NASDAQ:SRTS)

Research analysts at Alliance Global Partners began coverage on shares of Sensus Healthcare (NASDAQ:SRTS) in a research report issued to clients and investors on Friday, Marketbeat.com reports. The brokerage set a “buy” rating and a $7.50 price target on the stock. Alliance Global Partners’ price objective would suggest a potential upside of 76.47% from the stock’s previous close.

Several other equities analysts have also recently weighed in on SRTS. Wall Street Zen cut Sensus Healthcare from a “hold” rating to a “sell” rating in a report on Saturday, February 14th. Weiss Ratings reissued a “sell (d)” rating on shares of Sensus Healthcare in a report on Thursday, January 22nd. Finally, Maxim Group dropped their price target on Sensus Healthcare from $8.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, February 17th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Sensus Healthcare presently has an average rating of “Moderate Buy” and an average target price of $6.88.

Sensus Healthcare Trading Down 0.7%

NASDAQ:SRTS opened at $4.25 on Friday. Sensus Healthcare has a 1-year low of $3.03 and a 1-year high of $5.92. The business’s 50-day moving average price is $4.54 and its two-hundred day moving average price is $3.90. The firm has a market capitalization of $69.96 million, a price-to-earnings ratio of -9.04 and a beta of 1.22.

Sensus Healthcare (NASDAQ:SRTS) last released its quarterly earnings results on Thursday, February 12th. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.10). The business had revenue of $4.94 million during the quarter, compared to analyst estimates of $8.35 million. Sensus Healthcare had a negative net margin of 28.09% and a negative return on equity of 15.11%. Sell-side analysts predict that Sensus Healthcare will post 0.32 earnings per share for the current year.

Institutional Trading of Sensus Healthcare

Several institutional investors and hedge funds have recently modified their holdings of the business. Opes Wealth Management LLC bought a new position in Sensus Healthcare in the third quarter valued at about $50,000. Vise Technologies Inc. acquired a new stake in shares of Sensus Healthcare in the 2nd quarter valued at approximately $52,000. XTX Topco Ltd bought a new stake in shares of Sensus Healthcare during the 4th quarter valued at approximately $77,000. Jane Street Group LLC bought a new stake in shares of Sensus Healthcare during the 4th quarter valued at approximately $79,000. Finally, Mindset Wealth Management LLC increased its position in Sensus Healthcare by 28.1% during the 3rd quarter. Mindset Wealth Management LLC now owns 50,100 shares of the company’s stock worth $157,000 after purchasing an additional 11,000 shares in the last quarter. 25.30% of the stock is currently owned by institutional investors.

About Sensus Healthcare

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.